DBV Technologies | DBVT - 现金及等价物



金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 727.7M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


现金及等价物 更改 日
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amarin USD 131.06M 3.6M 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
DBV Technologies USD 194.17M 124.33M 2025-12
Esperion Therapeutics USD 156.16M 11.69M 2026-03
Galectin Therapeutics USD 25.6M 2.04M 2024-06
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Incyte USD 4.02B 435.22M 2026-03
Insmed USD 582.19M 71.74M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
United Therapeutics USD 1.28B 277.4M 2026-03